PFF In The Media

Pulmonary Fibrosis Foundation adds 2 experts to help guide its future

The Pulmonary Fibrosis Foundation (PFF), an advocacy group dedicated to advancing care for people with pulmonary fibrosis, has added two new members to its board of directors.

Link to Article

Pulmonary fibrosis foundation adds two to board

Chicago pulmonologist Dr. Bradford Bemiss and Detroit pulmonary disease specialist Dr. Krishna Thavarajah have been named to the board of directors of the Pulmonary Fibrosis Foundation

Link to Article

Tech Can't Heal a Broken System: What Healthcare Leaders Want You to Know

As healthcare grows more digital, leaders across medicine, nursing, informatics, and patient advocacy are asking a more fundamental question: how can new technologies strengthen care rather than complicate it?

Link to Article

PFF Walk raises awareness about pulmonary fibrosis

Scott traveled from Arizona to Pittsburgh for a double lung transplant and watched Talk Pittsburgh while he was at the hospital. Now this weekend, Scott and his husband Carey will be walking to raise awareness and support for pulmonary fibrosis.

Link to Article

By working together, we will be able to have better therapies and a cure for PF

If you are a patient and not participating in research, I would like to ask you why.

Link to Article

How to Exercise With Idiopathic Pulmonary Fibrosis

When you have idiopathic pulmonary fibrosis (IPF), shortness of breath, chronic fatigue, and a nagging, dry cough can make exercise feel uncomfortable and even seem intimidating for some.

Link to Article

Travel Tips for Idiopathic Pulmonary Fibrosis

Traveling with idiopathic pulmonary fibrosis (IPF) may take extra planning, but it’s possible.

Link to Article

Inhaled treprostinil lowers FVC decline in IPF at 52 weeks

With receipt of inhaled treprostinil for 52 weeks, adults with idiopathic pulmonary fibrosis had less FVC decline compared with those receiving placebo, according to results published in The New England Journal of Medicine.

Link to Article

St. Luke’s designated as pulmonary center

St. Luke's University Health Network has been designated as a Care Center within the Pulmonary Fibrosis Foundation's nationally recognized Care Center Network, expanding access to specialized care for people living pulmonary fibrosis and interstitial lung disease in the region.

Link to Article

Pulmonary Fibrosis Foundation expands national care network, strengthening access to expert lung disease care

The Pulmonary Fibrosis Foundation’s Care Center Network has grown to include 96 sites in 40 states as part of its first expansion since 2023, marking a milestone in strengthening access to multidisciplinary care for people living with pulmonary fibrosis (PF) and interstitial lung disease (ILD).

Link to Article

Partner with PFF through advocacy and education to benefit PF community

The third pillar of 5-year strategic plan focuses on improving patients' lives

Link to Article

Christine Ebersole, Jelani Alladin and More to Star in BROADWAY BELTS FOR PFF!

The lineup has been revealed for the 16th annual Broadway Belts for PFF! on Monday, March 9, at SONY Hall with a simultaneous virtual livestream.

Link to Article

Q&A: FDA accepts IPF biomarker panel into qualification program

The FDA Center for Drug Evaluation and Research has accepted a letter of intent for the first biomarker for idiopathic pulmonary fibrosis into its Biomarker Qualification Program, according to a press release.

Link to Article

Extended-release nalbuphine lowers cough frequency in IPF-associated chronic cough

Patients with idiopathic pulmonary fibrosis-associated chronic cough who received twice-daily oral extended release nalbuphine for 6 weeks had decreases in 24-hour cough frequency, according to data published in JAMA.

Link to Article

How the PFF’s 5-year plan seeks to expand access to expert care

I’ve been writing recently about the four pillars of the Pulmonary Fibrosis Foundation’s (PFF) new five-year strategic plan introduced last year, called “The PFF Is ME.” In December, I explained the first pillar, Accelerate Research. The second pillar, Expand Access to Expert Care, is a concern for all patients in the pulmonary fibrosis (PF) community. I had the opportunity to interview the champion of the plan’s second pillar, Sonye Danoff, MD, PhD, the senior medical adviser for the PFF’s Care Center Network (CCN).

Link to Article

A first for IPF biomarkers: PROLIFIC risk score nears FDA qualification

The PROLIFIC Risk Score, a multi-biomarker blood test for idiopathic pulmonary fibrosis (IPF), has taken a significant step forward in regulatory recognition. In December 2025, the FDA’s Center for Drug Evaluation and Research accepted PROLIFIC’s Letter of Intent into its Biomarker Qualification Program; the first time an IPF biomarker has reached this milestone. This step underscores the potential of the Risk Score to improve how patients are stratified in clinical trials and how disease progression is predicted, addressing a key challenge in IPF drug development and patient care.

Link to Article

1World Radio Episode 89 - Julie Halston

Learn about Julie Halston and her late husband Ralph Howard's journey with pulmonary fibrosis, the work of the Pulmonary Fibrosis Foundation and Julie's annual event Broadway Belts for PFF. For more information about the Pulmonary Fibrosis Foundation you can go to https://www.pulmonaryfibrosis.org

Link to Article

Angiotensin-converting enzyme inhibitor use before IPF diagnosis lowers mortality risk

Chronic fatigue is a common symptom of idiopathic pulmonary fibrosis (IPF), and may affect as many as 95 percent of all individuals living with this condition. Fatigue can have a significant impact on quality of life, and it generally stems from several factors including difficulty breathing, disrupted sleep, anxiety and depression, and medications used to treat IPF.

Link to Article